Claims
- 1. A method to provide an antitumor treatment to a tumor-bearing subject, comprising: administering a composition containing a therapeutically effective amount of epothilone D to such subject by intravenous infusion.
- 2. The method of claim 1 wherein the concentration of epothilone D in said composition is between about 0.25 mg/mL and about 2.0 mg/mL.
- 3. The method of claim 2 wherein the concentration of epothilone D in said composition is between about 0.5 mg/mL and about 1.0 mg/mL.
- 4. The method of claim 3 wherein the concentration of epothilone D in said composition is about 0.5 mg/mL.
- 5. The method of claim 1 wherein the amount of epothilone D administered in said step of administering by intravenous infusion is at least about 100 mg of epothilone D per square meter of the surface area of such subject.
- 6. The method of claim 5 wherein the amount of epothilone D administered in said step of administering by intravenous infusion is at least about 120 mg of epothilone D per square meter of the surface area of such subject.
- 7. The method of claim 1 wherein said administering by intravenous infusion is performed for less than about 6 hours.
- 8. The method of claim 13, further including providing a treatment cycle comprising performing said step of administering by intravenous infusion at least once about every seven days throughout a delivery period of about twenty-one consecutive days.
- 9. The method of claim 8, further including repeating said step of administering by intravenous infusion twice over about fourteen days throughout said delivery period of about twenty-one consecutive days.
- 10. The method of claim 8, further including the step of evaluating the status of such subject to determine whether to administer additional epothilone D to such subject.
- 11. The method of claim 10, wherein said treatment cycle has a duration of about twenty-eight days.
- 12. The method of claim 11, wherein said delivery period begins on the first day of said treatment cycle.
- 13. The method of claim 11, further including the step of repeating said treatment cycle after the completion of said treatment period.
- 14. The method of claim 1, further including the step of providing to such subject a treatment cycle comprising performing said step of administering by intravenous infusion once about every twenty-four hours throughout a delivery period of about seventy-two hours.
- 15. The method of claim 14, wherein said treatment cycle has a duration of about fourteen consecutive days.
- 16. The method of claim 15, further comprising repeating said treatment cycle two times over about twenty-eight consecutive days.
- 17. The method of claim 16, wherein the amount of epothilone D administered in said step of administering by intravenous infusion is at least about 40 mg of epothilone D per square meter of the surface area of such subject.
- 18. The method of claim 17, wherein the amount of epothilone D administered in said step of administering by intravenous infusion is at least about 50 mg of epothilone D per square meter of the surface area of such subject.
- 19. The method of claim 16, wherein said step of administering by intravenous infusion is performed over a period of less than about two hours.
- 20. A method to provide an antitumor treatment to a tumor-bearing subject, comprising: administering a composition containing a therapeutically effective amount of epothilone D to such subject by intravenous infusion, wherein said intravenous infusion is performed continuously for a period of about twenty-four hours.
- 21. The method of claim 20, wherein said step of administering includes providing a loading dose.
- 22. The method of claim 21, wherein said loading dose is followed by a continuous infusion.
- 23. The method of claim 22, wherein said step of administering delivers a dose of less than about 250 mg of said epothilone D to such subject.
- 24. The method of claim 22, wherein said step of administering delivers a dose of about 70 mg of said epothilone D to such subject.
- 25. The method of claim 24, wherein said step of administering delivers a dose of about 200 mg of said epothilone D to such subject.
1 CROSS REFERENCE TO RELATED U.S. PATENT APPLICATIONS
[0001] This patent application claims priority under 35 U.S.C. § 119(e) as a continuation-in-part of Provisional U.S. Patent Application Serial No. 60/382,166, which is incorporated herein by reference for all purposes.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60382166 |
May 2002 |
US |